Growth Hormone in Obese Cases With Covid-19
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04532554 |
Recruitment Status :
Withdrawn
(No participants enrolled)
First Posted : August 31, 2020
Last Update Posted : September 16, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Covid19 | Drug: Growth Hormone Drug: Placebo | Phase 4 |
It is well known that lymphoid organs such the thymus, the spleen and peripheral blood produce growth hormone (GH) and GH receptor is expressed on different subpopulations of lymphocytes. Many in vitro and in animal studies demonstrate an important role of GH in immunoregulation. GH stimulates T and B cells proliferation and immunoglobulin synthesis, enhances the maturation of myeloid progenitor cells and is also able to modulate cytokine response.
The use of growth hormone in obese cases with COVID-19 may help them to recover earlier.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The Impact of Growth Hormone in Obese Cases With Covid-19 |
Estimated Study Start Date : | October 26, 2020 |
Estimated Primary Completion Date : | December 10, 2020 |
Estimated Study Completion Date : | December 20, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Growth hormone
Recombinant GH will be used for those patients
|
Drug: Growth Hormone
Recombinant growth hormone will be used
Other Name: Recombinant growth hormone |
Placebo Comparator: Placebo
Saline will be used
|
Drug: Placebo
Saline injection with the same amount
Other Name: Saline |
- Need for hospitalization [ Time Frame: one to two weeks ]need to be hospitalized due to deterioration
- Time to recovery [ Time Frame: one to four weeks ]Time to recovery from symptoms and signs
- Percentage of reduction in CRP [ Time Frame: one to two weeks ]Percentage of reduction in CRP
- Percentage of reduction in LDH [ Time Frame: one to two weeks ]Percentage of reduction in LDH
- Percentage of reduction in Ferritin [ Time Frame: one to two weeks ]Percentage of reduction in Ferritin
- Time to recovery from leucopenia [ Time Frame: one to two weeks ]Time to recovery from leucopenia

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Obese with BMI > 30
Exclusion Criteria:
- History of hypersensitivity to GH

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04532554
Egypt | |
Asalam | |
Maadi, Cairo, Egypt, 11433 |
Principal Investigator: | Emad R Issak, MD | Assalam Clinics |
Responsible Party: | ClinAmygate |
ClinicalTrials.gov Identifier: | NCT04532554 |
Other Study ID Numbers: |
PR0015 |
First Posted: | August 31, 2020 Key Record Dates |
Last Update Posted: | September 16, 2020 |
Last Verified: | September 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
COVID-19 Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia Virus Diseases Coronavirus Infections Coronaviridae Infections |
Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |